Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

被引：20

作者：

Ludwig, Heinz ^{[1
]}

Poenisch, Wolfram ^{[2
]}

Knop, Stefan ^{[3
]}

Egle, Alexander ^{[4
]}

Hinke, Axel ^{[5
]}

Schreder, Martin ^{[6
]}

Lechner, Daniel ^{[7
]}

Hajek, Roman ^{[8
]}

Gunsilius, Eberhard ^{[9
]}

Petzer, Andreas ^{[10
]}

Weisel, Katja ^{[11
]}

Niederwieser, Dietger ^{[2
]}

Einsele, Hermann ^{[3
]}

Willenbacher, Wolfgang ^{[9
,12
]}

Rumpold, Holger ^{[13
]}

Pour, Ludek ^{[14
]}

Jelinek, Tomas ^{[8
]}

Krenosz, Karl Jochen ^{[15
]}

Meckl, Angela ^{[1
]}

Nolte, Sandra ^{[16
]}

Melchardt, Thomas ^{[4
]}

Greil, Richard ^{[4
]}

Zojer, Niklas ^{[6
]}

机构：

[1] Wilhelminen Hosp, Wilhelminen Canc Res Inst, Ctr Oncol & Hematol, Dept Med 1, Vienna, Austria

[2] Univ Leipzig, Dept Hematol, Leipzig, Germany

[3] Wuerzburg Univ Med Ctr, Dept Internal Med 2, Div Hematol & Med Oncol, Wurzburg, Germany

[4] Paracelsus Med Univ Salzburg, Dept Internal Med Haematol Med Oncol Hemostaseol, Ctr Clin Canc & Immunol Trials,Oncol Ctr, Salzburg Canc Res Inst,Canc Cluster Salzburg, Salzburg, Austria

[5] CCRC Canc Clin Res Consulting, Dusseldorf, Germany

[6] Wilhelminen Hosp, Ctr Oncol & Hematol, Dept Med 1, Vienna, Austria

[7] Ordensklinikum Linz Elisabethinen, Dept Med Hematol Stem Cell Transplantat Hemostase, Linz, Austria

[8] Fak Nemocnice Ostrava, Ostrava, Czech Republic

[9] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[10] Ordensklinikum Linz Barmherzige Schwestern, Dept Internal Med 1, Linz, Austria

[11] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[12] Oncotyrol, Ctr Personalized Canc Med, Innsbruck, Austria

[13] Acad Teaching Hosp Feldkirch, Dept Oncol Hematol & Gastroenterol, Feldkirch, Austria

[14] Univ Hosp Brno, Dept Internal Hematol & Oncol, Brno, Czech Republic

[15] Kepler Univ Klinikum GmbH, Dept Internal Med 3, Med Campus 3, Linz, Austria

[16] Charite, Dept Med, Div Psychosomat Med, Berlin, Germany

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 02期

关键词：

Multiple myeloma; quality of life; ixazomib; thalidomide; relapsed; refractory disease; REPORTED OUTCOMES; EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; ORAL IXAZOMIB; LENALIDOMIDE; CARFILZOMIB; SYMPTOMS; CHEMOTHERAPY; SURVIVAL; QLQ-C30;

D O I：

10.1080/10428194.2019.1666381

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (>= 10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.

引用

页码：377 / 386

页数：10

共 38 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review Perspectives From Industry, the Food and Drug Administration, and the Patient [J].

Basch, Ethan ;

Geoghegan, Cindy ;

Coons, Stephen Joel ;

Gnanasakthy, Ari ;

Slagle, Ashley F. ;

Papadopoulos, Elektra J. ;

Kluetz, Paul G. .

JAMA ONCOLOGY, 2015, 1 (03) :375-379

[3] The logrank test [J].

Bland, JM ;

Altman, DG .

BRITISH MEDICAL JOURNAL, 2004, 328 (7447) :1073-1073

[4] The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis [J].

Carrasco, Daniel R. ;

Sukhdeo, Kumar ;

Protopopova, Marina ;

Sinha, Raktim ;

Enos, Miriam ;

Carrasco, Daniel E. ;

Zheng, Mei ;

Mani, Mala ;

Henderson, Joel ;

Pinkus, Geraldine S. ;

Munshi, Nikhil ;

Horner, James ;

Ivanova, Elena V. ;

Protopopov, Alexei ;

Anderson, Kenneth C. ;

Tonon, Giovanni ;

DePinho, Ronald A. .

CANCER CELL, 2007, 11 (04) :349-360

[5] Distress, Fatigue, and Sexuality Understanding and treating concerns and symptoms in patients with multiple myeloma [J].

Catamero, Donna ;

Noonan, Kimberly ;

Richards, Tiffany ;

Faiman, Beth ;

Manchulenko, Cindy ;

Devine, Hollie ;

Bertolotti, Page ;

Gleason, Charise .

CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (05) :7-+

[6] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[7] An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma [J].

Cocks, K. ;

Cohen, D. ;

Wisloff, F. ;

Sezerc, O. ;

Lee, S. ;

Hippe, E. ;

Gimsing, P. ;

Turesson, I. ;

Hajek, R. ;

Smith, A. ;

Graham, L. ;

Phillips, A. ;

Stead, M. ;

Velikova, G. ;

Brown, J. .

EUROPEAN JOURNAL OF CANCER, 2007, 43 (11) :1670-1678

[8] Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [J].

Cocks, K. ;

King, M. T. ;

Velikova, G. ;

de Castro, G., Jr. ;

St-James, M. Martyn ;

Fayers, P. M. ;

Brown, J. M. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (11) :1713-1721

[9] Recommendations for the assessment of progression in randomised cancer treatment trials [J].

Dancey, J. E. ;

Dodd, L. E. ;

Ford, R. ;

Kaplan, R. ;

Mooney, M. ;

Rubinstein, L. ;

Schwartz, L. H. ;

Shankar, L. ;

Therasse, P. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :281-289

[10] Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide [J].

Delforge, Michel ;

Minuk, Leonard ;

Eisenmann, Jean-Claude ;

Arnulf, Bertrand ;

Canepa, Letizia ;

Fragasso, Alberto ;

Leyvraz, Serge ;

Langer, Christian ;

Ezaydi, Yousef ;

Vogl, Dan T. ;

Giraldo-Castellano, Pilar ;

Yoon, Sung-Soo ;

Zarnitsky, Charles ;

Escoffre-Barbe, Martine ;

Lemieux, Bernard ;

Song, Kevin ;

Bahlis, Nizar Jacques ;

Guo, Shien ;

Monzini, Mara Silva ;

Ervin-Haynes, Annette ;

Houck, Vanessa ;

Facon, Thierry .

HAEMATOLOGICA, 2015, 100 (06) :826-833

← 1 2 3 4 →